Treats metastatic carcinoid tumors. ANDA 75957, held by Meitheal. Octreotide Acetate.
As of Nov 16, 2026, ANDA 75957 (Octreotide Acetate), held by Meitheal, was first approved by FDA on Oct 3, 2005, with 7 approved supplements and 0 published complete response letters.
Octreotide Acetate Injection is a somatostatin analogue indicated: Acromegaly: To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. Carcinoid Tumors: For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. Vasoactive Intestinal Peptide Tumors (VIPomas): For the treatment of profuse watery diarrhea associated with VIP-secreting tumors.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 3, 2005 | Original application | Approved | None posted |
| Octreotide AcetateEQ 0.05MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Octreotide AcetateEQ 0.1MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Octreotide AcetateEQ 0.5MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Aug 8, 2023 | Supplement 35Labeling · Standard review | Approved | None posted |
| Aug 8, 2023 | Supplement 33Labeling · Standard review | Approved | None posted |
| Aug 8, 2023 | Supplement 32Labeling · Standard review | Approved | None posted |
| Nov 4, 2019 | Supplement 28Labeling · Standard review | Approved | None posted |
| Jun 27, 2017 | Supplement 25Labeling · Standard review | Approved | None posted |
| Jun 28, 2012 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jun 28, 2012 | Supplement 11Labeling | Approved | None posted |
| Oct 3, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters